HomeCompareMYMD vs EQR

MYMD vs EQR: Dividend Comparison 2026

MYMD yields 110.50% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MYMD wins by $5.89M in total portfolio value
10 years
MYMD
MYMD
● Live price
110.50%
Share price
$1.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$2,132,830.87
Full MYMD calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — MYMD vs EQR

📍 MYMD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYMDEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYMD + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYMD pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYMD
Annual income on $10K today (after 15% tax)
$9,392.27/yr
After 10yr DRIP, annual income (after tax)
$1,812,906.24/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, MYMD beats the other by $1,809,659.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYMD + EQR for your $10,000?

MYMD: 50%EQR: 50%
100% EQR50/50100% MYMD
Portfolio after 10yr
$2.99M
Annual income
$1,068,325.24/yr
Blended yield
35.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MYMD
No analyst data
Altman Z
-5.6
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYMD buys
0
EQR buys
0
No recent congressional trades found for MYMD or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYMDEQR
Forward yield110.50%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$5.93M$40.5K
Annual income after 10y$2,132,830.87$3,819.61
Total dividends collected$5.35M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: MYMD vs EQR ($10,000, DRIP)

YearMYMD PortfolioMYMD Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$21,750$11,049.72$11,248$547.57+$10.5KMYMD
2$45,733$22,460.60$12,701$666.53+$33.0KMYMD
3$93,072$44,137.91$14,405$814.59+$78.7KMYMD
4$183,537$83,949.70$16,413$999.84+$167.1KMYMD
5$351,102$154,717.47$18,795$1,232.92+$332.3KMYMD
6$652,287$276,608.54$21,639$1,527.95+$630.6KMYMD
7$1,178,220$480,272.57$25,057$1,903.80+$1.15MMYMD
8$2,071,454$810,758.34$29,197$2,385.87+$2.04MMYMD
9$3,548,616$1,332,160.25$34,250$3,008.70+$3.51MMYMD
10$5,929,850$2,132,830.87$40,467$3,819.61+$5.89MMYMD

MYMD vs EQR: Complete Analysis 2026

MYMDStock

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Full MYMD Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MYMD vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYMD vs SCHDMYMD vs JEPIMYMD vs OMYMD vs KOMYMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.